[The Mutated Gene Sequenced by NGS and the Correlation of Their Coexistent Mutual Exclusiveness in NPM1 Mutated Acute Myeloid Leukemia]

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2021 Dec;29(6):1733-1740. doi: 10.19746/j.cnki.issn.1009-2137.2021.06.007.
[Article in Chinese]

Abstract

Objective: To analyze the clinicobiological heterogeneity of NPM1 mutated (NPM1mut) acute myeloid leukemia (AML) detected by next generation sequencing (NGS) and their coexistence and mutual exclusivity relationship in the AML subtype.

Methods: The NGS data based on 112 genes related to blood disease in 238 newly diagnosed patients with NPM1mut were collected. The χ2 test and non-parametric test were used to analyze the distribution correlation between the genes in the mutational spectrum.

Results: Among all the patients, at least one co-mutation was detected out. The median number per case of the mutated genes, including NPM1mut was 4.5 (range 2-14), among them, there were 5.0 (range 2-10) for NPM1mut/FLT3-ITD+ and 4.0 (range 2-14) for NPM1mut/FLT3-ITD- cases, but it was no significant difference between the two groups (P=0.378). A total of 240 NPM1 mutational events were detected out in entire 238 NPM1mut patients, of which 10 (4.2%) were missense mutations, and were all found in NPM1mut/FLT3-ITD- patients. Most (9/10, 90%) of these NPM1 missense mutations were accompanied by AML subtype-defining cytogenetic or molecular abnormalities, of which 7 patients were in low risk or 2 in high risk. The most common NPM1mut coexisting mutations were DNMT3A (104, 43.7%), followed were FLT3-ITD (95, 39.9%) and FAT1 (57, 23.9%), FLT3-ITD and DNMT3A showed significant coexistence (P=0.005). FLT3-ITD showed significantly reciprocal exclusivity with FLT3-nonITD (P<0.001), NRAS (P<0.001), PTPN11 (P=0.017) and IDH1 (P=0.005), and showed an exclusivity inclination with KRAS (P=0.073). In addition, FLT3-nonITD along with KRAS (P=0.035), NRAS along with KRAS (P=0.008) and PTPN11 (P=0.039) coexisted significantly.

Conclusion: Prognoses of AML involving less common NPM1 missense mutations should be stated on a case by case basis. The mutational landscape and co-occurrence and mutual exclusivity correlations of NPM1mut AML provide a mechanism explaining biological diversity and clinical heterogeneity in this AML subset.

题目: NPM1突变急性髓系白血病二代测序突变基因谱及共存互斥相关性分析.

目的: 分析NPM1突变(NPM1mut)急性髓系白血病(AML)患者二代测序(NGS)检测的突变基因谱及其共存互斥关系,以解释NPM1mut AML的临床生物学异质性.

方法: 收集238例成人初诊NPM1mut患者基于112种血液病相关基因的NGS资料,采用χ2检验和非参数检验分析突变谱基因间分布相关性.

结果: 全部NPM1mut患者均检出至少1个共存突变。包括NPM1mut,中位数突变基因个数/每例为4.5 (2-14)个。其中NPM1mut/FLT3-ITD+者突变基因个数为5.0 (2-10)个,多于NPM1mut/FLT3-ITD-者[4.0(2-14)个],但两者间无统计学差异(P=0378)。全部238例NPM1mut患者共检出240例NPM1突变事件,其中10个(10/240, 4.2%)为错义突变,且均见于NPM1mut/FLT3-ITD-者。这些错义突变绝大多数(9/10, 90%)同时合并AML亚型定义的细胞遗传学或分子学异常,且均为低危(7例)或高危组(2例)。分析相对常见(突变率>5%)的NPM1mut共存突变基因谱,最常见的为DNMT3A(104例, 43.7%),其次为FLT3-ITD(95例, 399%)和FAT1(57例, 23.9%)。FLT3-ITD与DNMT3A间呈显著性突变共存(P=0.005)。FLT3-ITD与FLT3-nonITD(P<0.001)、NRAS(P<0.001)、PTPN11(P=0.017)以及IDH1(P=0.005)间呈显著性突变排斥,与KRAS间呈临界意义突变排斥倾向(P=0.073)。FLT3-nonITD与KRAS间(P=0.035)、NRAS与KRAS(P=0.008)和PTPN11(P=0.039)间显著性突变共存.

结论: 阐述NPM1mut患者的临床预后时,应区别对待相对少见的错义突变类型。检测NPM1mutAML突变基因谱全貌和了解突变间共存关系,为患者生物学多样性和临床异质性提供了机制解释.

MeSH terms

  • Base Sequence
  • High-Throughput Nucleotide Sequencing
  • Humans
  • Leukemia, Myeloid, Acute* / genetics
  • Mutation
  • Nuclear Proteins* / genetics

Substances

  • Nuclear Proteins